Evidence-based recommendations for the use of WBC-reduced cellular blood components.
Ratko
T A
TA
Technology Assessment Group, Clinical Practice Advancement Center, University Health System Consortium, Oak Brook, Illinois 60523-1890, USA. ratko@uhc.edu
Cummings
J P
JP
Oberman
H A
HA
Crookston
K P
KP
DeChristopher
P J
PJ
Eastlund
D T
DT
Godwin
J E
JE
Sacher
R A
RA
Yawn
D H
DH
Matuszewski
K A
KA
D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D001793:Blood Preservation; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D006801:Humans; D007937:Leukapheresis / Q000191:economics / Q000379:methods / Q000592:standards; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence; D016635:Universal Precautions